Mirror Now
@mirrornow·2.2M subscribers·145K videos
AIIMS begins human clinical trials of Covaxin developed by Bharat Biotech, ICMR and NIV
Posted
July 20, 2020
Views
111
Likes
1
Engagement
0.90%
July 20, 2020
111
1
0.90%
Every word spoken in this episode is indexed. Type any phrase to jump straight to the moment it was said.
Type any word or phrase that may have been spoken. Click a result to seek the player to that exact moment.
Try a name, a topic, or a quoted line
See what was published immediately before and after this episode.
3:14Now PlayingThe All India Institute of Medical Sciences (AIIMS) in Delhi, which is one among 12 sites for the phase I and phase II of human clinical trials of the indigenously developed Covid-19 vaccine candidate 'Covaxin', has started the human trial.
Over 1800 volunteers have registered themselves in AIIMS for the trial.
These volunteers will be undergoing a battery of tests including RTPCR and serological test for screening of COVID19 before they are administered Covaxin.
Each of the volunteer, who is undergoing the trial would be insured for Rs 50 lakh, said Sanjay Rai, the principal investigator.
The Covaxin has been developed by the Hyderabad-based Bharat Biotech in collaboration with the Indian Council for Medical Research (ICMR) and the National Institute of Virology (NIV).
SUBSCRIBE NOW for more such videos ►
For More Updates ►
Like us on Facebook ►
Follow us on Twitter ►
Follow us on Instagram ►
Sentinel Indexing in Progress
Metadata and chapters are available. Claim extraction for this episode is pending.
All video content is delivered via YouTube embedded players in accordance with the YouTube Terms of Service. Sentinel provides research tools that promote discovery and accountability across political media.
